Fig. 5: Orally administered AB928 augments CAR T cell activation in vivo.
From: Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function
a Schematic illustration of the experimental setup. b–d CAR+ T cells in the spleen were tracked and phenotyped by flow cytometry at the end of the experiment. Data are shown as mean ± SEM of control n = 10 mice and AB928 n = 8 mice. *P < 0.05, ***P < 0.001 by two-sided t test.
